# Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

> **NCT05535322** · — · COMPLETED · sponsor: **Ana Palanca** · enrollment: 26944 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** GLP-1RA
- **DRUG:** SGLT2i
- **DRUG:** Insulin
- **DRUG:** Miscellany

## Key facts

- **NCT ID:** NCT05535322
- **Lead sponsor:** Ana Palanca
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2022-09-01
- **Target enrollment:** 26944 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05535322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05535322, "Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05535322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*